Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues

BACKGROUND: Optimal cytoreduction to no residual disease (R0) correlates with improved disease outcome for high-grade serous ovarian cancer (HGSOC) patients. Treatment of HGSOC patients with neoadjuvant chemotherapy, however, may select for tumor cells harboring alterations in hallmark cancer pathwa...

Descripción completa

Detalles Bibliográficos
Autores principales: Penick, Emily R., Bateman, Nicholas W., Rojas, Christine, Magana, Cuauhtemoc, Conrads, Kelly, Zhou, Ming, Hood, Brian L., Wang, Guisong, Parikh, Niyati, Huang, Ying, Darcy, Kathleen M., Casablanca, Yovanni, Mhawech-Fauceglia, Paulette, Conrads, Thomas P., Maxwell, G. Larry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531351/
https://www.ncbi.nlm.nih.gov/pubmed/36195845
http://dx.doi.org/10.1186/s12014-022-09372-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531351/
https://www.ncbi.nlm.nih.gov/pubmed/36195845
http://dx.doi.org/10.1186/s12014-022-09372-y

Ejemplares similares